Concepedia

A decision process for drug discovery in retinoblastoma

María Belén Cancela, Santiago Zugbi, Ursula Winter, Ana Laura Martinez, Claudia Sampor, Mariana Sgroi, Jasmine H. Francis, Ralph Garippa, David H. Abramson, Guillermo Chantada,

Investigational New Drugs · 2020 · 19 citations · 92 references

DOIFull text

Open access

Concepts

References

92

A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays

Ji-Hu Zhang, Thomas D.Y. Chung, Kevin R. Oldenburg · SLAS DISCOVERY · 1999 · 7K citations · Full text

, , +16

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

Tilman Oltersdorf, Steven W. Elmore, Alexander R. Shoemaker et al. · Nature · 2005 · 3.4K citations

, , +14

Methylene blue in photodynamic therapy: From basic mechanisms to clinical applications

João Paulo Tardivo, Auro del Giglio, Carla de Oliveira et al. · Photodiagnosis and Photodynamic Therapy · 2005 · 899 citations

, , +17

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

Wyndham H. Wilson, Owen A. O’Connor, Myron S. Czuczman et al. · The Lancet Oncology · 2010 · 853 citations · Full text

, , +15

Global Retinoblastoma Presentation and Analysis by National Income Level

Ido Didi Fabian, Abdallah Elhassan, Shehu U. Abdullahi et al. · JAMA Oncology · 2020 · 369 citations · Full text

, , +16